Summary
New therapeutic options and new information from clinical trials have improved treatment of type 2 diabetes, but also increased the complexity of clinical decisions by providing more options. This added complexity applies to the transition from oral therapies to insulin, as well as other aspects of treatment. Discussion of the transition from oral to insulin therapy is best started by reviewing the process of glycemic management of type 2 diabetes in general.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Riddle MC. Glycemic management of type 2 diabetes: an emerging strategy with oral agents, insulins, and combinations. Endocrinol Metab Clin N Am 2005;34: 77–98
Riddle M. Combining sulfonylureas and other oral agents. Am J Med 2000;108(6A): 15S–22S
Yki-Jarvinen H. Combination therapies with insulin in type 2 diabetes. Diabetes Care 2001;24: 758–767
Inzucchi SE. Oral antihyperglycemic therapy for type 2 diabetes. JAMA 2002;287: 360–372
Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy. Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57) Diabetes Care 2002;25: 330–336
DeWitt DE, Hirsch IB. Outpatient insulin therapy in type 1 and type 2 diabetes mellitus. JAMA 2003;289: 2254–2264
Shichiri M, Kishikawa H, Ohkubo Y, Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2): B21–B29
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998:352: 837–853
UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: 854–865
Riddle MC. Sulfonylureas differ in effects on ischemic preconditioning – Is it time to retire glyburide? J Clin Endocrinol Metab 2003;88; 528–530
Schwartz TB, Meinert CL. The UGDP controversy: thirty-four years of contentious ambiguity laid to rest. Perspect Biol Med 2004;47: 564–574
Monami M, Luzzi C, Lamanna C, Chiasserini V, Addante F, Desideri CM, Masotti G, Marchionni N, Mannucci E. Three-year mortality in diabetic patients treated with different combinations of insulin secretagogues and metformin. Diabetes/Metabolism Res Rev 2006;22: 477–482
Chiasson J-L, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, the STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance. The STOP-NIDDM Trial. JAMA 2003;290: 486–494
Dormandy JA, Charbonnel B, Ekland DJA, Erdmann E, Massi-Benedetti M, Moules IK, Skene AM, Tan MH, Lefebvre PJ, Murray GD, Standl E, Wilcox RG, Wilhelmsen L, Betteridge J, Birkeland K, Golay A, Heine RJ, Koranyi L, Laakso M, Mokan M, Norkus A, Pirags V, Podar T, Scheen A, Scherbaum W, Shernthaner G, Schmitz O, Skrha J, Taton J, the PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366: 1279–1289
Hayward RA, Manning WG, Kaplan SJ, Wagner E, Greenfield S. Starting insulin therapy in patients with type 2 diabetes. JAMA 1997;278: 1663–1669
Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care 2004;27: 1535–1540
Yki-Jarvinen H. Thiazolidinediones. N Engl J Med 2004;351: 1106–1118
Schwartz S, Sievers R, Strange P, Lyness WH, Hollander P, the INS-2061 Study Team. Insulin 70/30 mix plus metformin versus triple oral therapy in the treatment of type 2 diabetes after failure of 2 oral agents: Efficacy, safety, and cost analysis. Diabetes Care 2003;26: 2238–2243
Dailey GE, Noor MA, Park J-S, Bruce S, Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: A randomized, double-blind trial. Am J Med 2004;116: 223–229
Aljabri K, Kozak SE, Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial. Am J Med 2004;116: 230–235
Rosenstock J, Sugimoto D, Strange P, Stewart JA, Soltes-Rak E, Dailey G, the Insulin Glargine 4014 Study Investigators. Diabetes Care 2006;29: 554–559
Kunhiraman BP, Jawa A, Fonseca VA. Potential cardiovascular risk benefits of insulin sensitizers. Endocrinol Metab Clin NA 2005;34: 117–136
Holman RR, Retnakaran R, Farmer A, Stevens R. PROactive study (Letter). Lancet 2006;367: 25–26
Uwaifo GI, Ratner RE. Novel pharmacologic agents for type 2 diabetes. Endocrinol Metab Clin NA 2005;34: 155–197
Riddle MC, Drucker DJ. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 2006;29: 435–449
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated pateints with type 2 diabetes. Diabetes Care 2005;28: 1092–1100
Buse JB, Henry RR, Han J, Kim DD, Fineman MS, Baron AD, the Exenatide-113 Clinical Study Group. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27: 2628–2635
Kendall DM, Riddle MC, Rosenstock J, Zhuang D, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28: 1083–1091
Riddle MC, Henry RR, Poon TH, Zhang B, Mac SM, Holcombe JH, Kim DD, Maggs DG. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diab/Metab Res Rev 2006;22: 483–491
Heine RJ, van Gall LF, Johns D, Mihm MJ, Widel MH, Brodows RG, the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial. Ann Intern Med 2005;143: 559–569
Riddle MC. Evening insulin strategy. Diabetes Care 1990;13: 676–686
Riddle MC. Timely initiation of basal insulin. Am J Med 2004;116(3A): 3S–9S
Wright A, Burden ACF, Paisey RB, Cull CA, Holman RR, the UK Prospective Diabetes Study Group. Sulfonylurea inadequacy: Efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002;25: 330–336
Yki-Jarvinen H, Kauppila M, Kujansuu E, Lahti J, Marjanen T, Niskanen L, Rahala S, Ryysy L, Salo S, Seppala P, Tulokas T, Vukari J, Karalainen J, Taskinen M-R.. Comparison of insulin regimens in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 1992;327: 1426–1433
Shank ML, DelPrato S, DeFronzo RA. Bedtime insulin/daytime glipizide: Effective therapy for sulfonylurea failures in NIDDM. Diabetes 1995;44: 165–172
Riddle MC, Schneider J, the Glimepiride Combination Group. Diabetes Care 1998;21: 1052–1057
Riddle MC, Rosenstock J, Gerich J, the Insulin Glargine 4002 Study Investigators. The Treat-to-Target Trial: Randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003;26: 3080–3086
Yki-Jarvinen H, Kauppinen-Makelin R, Tiikkainen M, Vahatalo M, Virtamo H, Nikkila K, Tulokas T, Hulme S, Hardy K, McNulty S, Hanninen J, Levanen H, Lahdenpera S, Lehtonen R, Ryysy L. Insulin glargine or NPH combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006;49: 442–451
Kennedy L, Herman WH, Strange P, Harris A, the GOAL A1c Team. Impact of active versus usual algorithmic titration of basal insulin and point-of-care versus laboratory measurements of HbA1c on glycemic control in type 2 diabetes: The Glycemic Optimization with Algorithms and Labs at Point of Care (GOAL A1C) Trial. Diabetes Care 2006;29: 1–8
Danne T, Lupke K, Walte K, von Scheutz W, Gall M-A. Insulin detemir is characterized by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults with type 1 diabetes. Diabetes Care 2003;26: 3087–3092
Hermansen K, Davies M, Derezinski R, Ravn GM, Clauson P, Home P, the Levemir Treat-to-Target Study Group. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin naivc-people with type 2 diabetes. Diabetes Care 2006;29: 1269–1274
Landstedt-Hallin L, Adamson U, Arner P, Bolinder J, Lins P-E. Comparison of bedtime NPH or preprandial regular insulin combined with glibenclamide in secondary sulfonylurea failure. Diabetes Care 1995;18: 1183–1186
Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care 1997;20: 1539–1542
Bastyr EJ, Stuart CA, Brodows RG, Schwartz S, Graf CJ, Zagar A, Robertson KE, the IOEZ Study Group. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. Diabetes Care 2000;23: 1236–1241
Poulsen MK, Henricksen JE, Hother-Nielsen O, Beck-Nielsen H. The combined effect of triple therapy with rosiglitazone, metformin, and insulin aspart in type 2 diabetic patients. Diabetes Care 2003;26: 33,273–33,279
Rave K, Bott S, Heinemann L, Sha S, Becker RHA, Willarize SA, Heise T. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care 2005;28: 1077–1082
Rosenstock J, Zinman B, Murphy PJ, Clement SC, Moore P, Bowering CK, Hendler R, Lan S-P, Cefalu WT. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med 2005;143: 549–558
Jacobsen LV, Sogaard B, Riis A. Pharmacokinetics and pharmacodynamics of a premixed formulation of soluble and protamine-retarded insulin aspart. Eur J Clin Pharmacol 2000;56: 399–403
Heise T, Weyer C, Serwas A, Heinrichs S, Osinga J, Roach P, Woodworth J, Gudat U, Heinemann L. Time-action profiles of novel premixed preparations of insulin lispro and NPL insulin. Diabetes Care 1998;21: 800–803
Boehm BO, Home PD, Behrend C, Kamp NM, Lindholm A. Premixed insulin aspart 30 vs premixed human insulin 30/70 twice daily: A randomized trial in type 1 and type 2 diabetic patients. Diab Med 2002;19: 393–399
Roach P, Yue L, Arora V, the Humalog Mix25 Study Group. Improved postprandial glycemic control during treatment with Humalog Mix25, a novel protamine-based insulin lispro formulation. Diabetes Care 1999;22: 1258–1261
Janka HU, Plewe G, Riddle MC, Kliebe-Frisch C, Schweitzer MA, Yki-Jarvinen H. Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for type 2 diabetes. Diabetes Care 2005;28: 254–259
Raskin P, Allen E, Hollander P. Initiating insulin therapy in type 2 diabetes: A comparison of biphasic and basal insulin analogs. Diabetes Care 2005;28: 260–265
Ejskjaer N, Rasmussen M, Kamp N, Lindholm A, Christiansen JS. Comparison of thrice daily ‘high‘ vs ‘medium‘ premixed insulin aspart with respect to evening and overnight glycaemic control in patients with type 2 diabetes. Diab Obes Metab 2003;5: 438–445
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Riddle, M.C. (2008). The Transition from Oral Agents to Combination Insulin/Oral Therapy. In: Feinglos, M.N., Bethel, M.A. (eds) Type 2 Diabetes Mellitus. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60327-043-4_11
Download citation
DOI: https://doi.org/10.1007/978-1-60327-043-4_11
Publisher Name: Humana Press
Print ISBN: 978-1-58829-794-5
Online ISBN: 978-1-60327-043-4
eBook Packages: MedicineMedicine (R0)